Bruker Co. (NASDAQ:BRKR) Shares Bought by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. increased its position in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 4.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 500,285 shares of the medical research company's stock after buying an additional 20,378 shares during the period. Balyasny Asset Management L.P. owned about 0.33% of Bruker worth $29,327,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Bruker by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company's stock valued at $118,081,000 after buying an additional 20,273 shares during the period. FIL Ltd grew its stake in Bruker by 262.3% in the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock valued at $114,978,000 after purchasing an additional 1,420,102 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Bruker by 22.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,687,364 shares of the medical research company's stock valued at $98,914,000 after purchasing an additional 313,171 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Bruker by 10.6% in the fourth quarter. Ameriprise Financial Inc. now owns 1,615,358 shares of the medical research company's stock valued at $94,692,000 after purchasing an additional 154,768 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. grew its stake in Bruker by 140.3% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company's stock valued at $66,930,000 after purchasing an additional 666,617 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on BRKR shares. Wells Fargo & Company cut their target price on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. The Goldman Sachs Group cut their target price on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday. UBS Group cut their target price on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday. Guggenheim reiterated a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Finally, Stifel Nicolaus cut their target price on Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a research note on Thursday. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Bruker currently has an average rating of "Moderate Buy" and a consensus target price of $60.10.

Bruker Stock Performance

Shares of Bruker stock traded up $2.55 on Monday, reaching $40.07. 818,583 shares of the stock were exchanged, compared to its average volume of 1,564,665. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. Bruker Co. has a twelve month low of $34.10 and a twelve month high of $79.78. The firm has a market capitalization of $6.07 billion, a price-to-earnings ratio of 52.63, a PEG ratio of 2.16 and a beta of 1.23. The business has a 50 day moving average price of $41.26 and a two-hundred day moving average price of $51.10.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The firm had revenue of $801.40 million during the quarter, compared to the consensus estimate of $763.83 million. During the same quarter in the previous year, the company posted $0.53 earnings per share. The company's revenue was up 11.0% compared to the same quarter last year. Analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date of this dividend was Monday, March 17th. Bruker's payout ratio is presently 26.32%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.